292 related articles for article (PubMed ID: 23014073)
1. Target therapies for radioiodine refractory advanced thyroid tumors.
Schlumberger M
J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
[TBL] [Abstract][Full Text] [Related]
2. Update on thyroid cancer treatment.
Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy of metastatic lesions of differentiated thyroid cancer.
Luster M; Hänscheid H; Freudenberg LS; Verburg FA
J Endocrinol Invest; 2012; 35(6 Suppl):21-9. PubMed ID: 23014070
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in radioiodine refractory thyroid cancer.
Pacini F; Brilli L; Marchisotta S
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
[TBL] [Abstract][Full Text] [Related]
5. New perspectives on the treatment of differentiated thyroid cancer.
Coelho SM; Carvalho DP; Vaisman M
Arq Bras Endocrinol Metabol; 2007 Jun; 51(4):612-24. PubMed ID: 17684624
[TBL] [Abstract][Full Text] [Related]
6. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
7. Molecular targeted therapies for patients with refractory thyroid cancer.
Chougnet C; Brassard M; Leboulleux S; Baudin E; Schlumberger M
Clin Oncol (R Coll Radiol); 2010 Aug; 22(6):448-55. PubMed ID: 20554167
[TBL] [Abstract][Full Text] [Related]
8. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
Spitzweg C; Bible KC; Hofbauer LC; Morris JC
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
[TBL] [Abstract][Full Text] [Related]
9. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
Fröhlich E; Wahl R
Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
[TBL] [Abstract][Full Text] [Related]
10. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies.
Pryma DA; Mandel SJ
J Nucl Med; 2014 Sep; 55(9):1485-91. PubMed ID: 25134528
[TBL] [Abstract][Full Text] [Related]
11. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
12. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
[TBL] [Abstract][Full Text] [Related]
13. [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies].
Malouf G; Baudin E; Soria JC; Schlumberger M
Bull Cancer; 2009 Jan; 96(1):95-101. PubMed ID: 19211364
[TBL] [Abstract][Full Text] [Related]
14. Redifferentiating agents in non-radioiodine avid cancer.
Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
[TBL] [Abstract][Full Text] [Related]
15. New molecular targeted therapies in thyroid cancer.
Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
[TBL] [Abstract][Full Text] [Related]
16. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
Molinaro E; Pieruzzi L; Viola D
J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
18. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
de la Fouchardière C
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
